Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252876 · ClinicalTrials.gov registry record · Phase 3
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
NCT00252876 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2,000 participants.
The verdict
NCT00252876, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
Interventions
- DRUG tesaglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252876
The ClinicalTrials.gov registry entry for NCT00252876 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tesaglitazar is the first listed.
NCT00252876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252876 about?
NCT00252876 is a clinical study titled "GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes". This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up...
What is the current status of trial NCT00252876?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2005-03. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00252876?
The interventions under investigation include: tesaglitazar (DRUG).
Who is sponsoring clinical trial NCT00252876?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.